Bones and Prostate Cancer

/Bones and Prostate Cancer

Can Radiotherapy (Radiation) for the Primary Tumors Benefit Men With Prostate CancerWith Distant Metastasis at Initial Diagnosis?

The common belief is that if you are diagnosed with prostate cancer that has already developed metastases only a systemic treatment will provide a life extending benefit. In other cancers it has been shown that the treatment of the primary tumor improves survival (tumor debulking). To find out if, in fact radiotherapy treatment of the primary tumor in prostate cancer with distant metastasis would provide a similar positive benefit, researchers evaluated the efficacy and toxicity of radiotherapy of the primary tumor in prostate cancer in men with metastasis. The study included 140 men with metastatic prostate cancer at initial diagnosis. [...]

Repeating Treatment with Radium-223 (Xofigo) is Safe and Effective

Radium-223 (Xofigo) is a drug for men with castrate resistant metastatic prostate cancer (mCRCP) who have multiple bone metastases. Radium-223 selectively targets bone metastases by mimicking calcium, which is attracted to the bone, especially to the fast growing areas of the tumor in the bone. It emits an alpha-emitting dose of radiation, which is mostly contained in the tumor due to the low spread of alpha waves). The current FDA approval for Radium-223 is for one course of 6 injections. Men have been asking if it is possible to have a re-treatment of Radium-223 once the disease has progressed after having [...]

CMS Continues To Limit Coverage For NaF-18 PET Scans For Bone Metastases

There has been a lot of buzz around the new scanning contrasts that have come into limited usage for evaluating metastasized cancer cells that are in the bones. Despite the enthusiasm from the prostate and breast cancer communities, CMS (Medicare) continues to limit its financial coverage for PET scans using the contrast NaF-18 even though it has displayed an increased ability to detect bone metastases. In the past CMS, had been willing to pay for positron emission tomography or NaF-18 PET scans as long as physicians collected and reported the data on its use and put it into a clinical [...]

Not All Men Benefit From Radium-223 (Xofigo)?

Researchers are now beginning to understand which men with castration-resistant prostate cancer (CRPC) might be helped by radium-223 (Xofigo), and for which men Xofigo will be a waste of time and money, and possibly cause harm. They have found that baseline ECOG performance status, alkaline phosphatase (ALP), hemoglobin (Hb) levels, and the concomitant use of abiraterone acetate (Zytiga) or denosumab were indicators for improved overall survival (OS) when radium-223 is used. These findings came from a phase IIIb follow-up to the pivotal phase III ALSYMPCA trial presented at the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC). Data from the post-hoc analysis showed [...]